Phosphate
maker Itafos posted a $48.6 million loss for the fourth-quarter ending Dec. 31,
2023, compared to year-ago net income of $29.3 million. The company said the
performance was primarily due to lower realized prices as a result of softer
global market conditions and a $66 million impairment of non-current assets at Arraias,
Brazil, partially offset by higher sales volumes and lower input costs.
“During
fourth-quarter 2023, we saw prices continue to strengthen off the lows of
second-quarter 2023, reflective of increasing demand and tighter US supply
fundamentals,” said G. David Delaney, Itafos CEO. “We expect to see conditions
continue into 2024. Going forward, the company will now provide guidance
associated with our expected sales volumes, capital expenditures, and other
relevant financial metrics. This change is consistent with peers in the
industry.”
Itafos
gave full-year 2024 sales volume guidance of 320,000-340,000 mt P205; SGA
expenses guidance of $17-$20 million; maintenance capex of $25-$35 million; and
growth capex of $35-$46 million.
Itafos
added that it saw an extremely strong fall season, which resulted in improved
prices from the summer and a continued tightening of North American phosphate
fertilizer supply. The company expects a stable market moving forward due to
ongoing tight supply situation coupled with softer crop prices.
Delaney
said work continues on the company’s Husky 1/North Dry Ridge capital project,
which he said remains on schedule and on budget. The company expects to begin
mining activities in fourth-quarter 2025 onward, providing an uninterrupted
supply as its Rasmussen Valley Mine reaches the end of its useful life.
Delaney
said Itafos continues to explore and evaluate various strategic alternatives to
enhance value for shareholders. The process was announced by the Board of
Directors in first-quarter 2023 (GM March 17, 2023).
In
other news, Itafos said that as of Dec. 31, 2023, it has completed the wind-down
process of its Mantaro phosphate mine project in Junin, Peru, which was
previously owned by Stonegate Agricom Ltd. (GM July 21, 2017; May 26,
2017).
Fourth-quarter
Itafos revenues were $119 million, down from the year-ago $135.2 million, while
adjusted EBITDA was $29.5 million, down from $50.1 million.
The
Itafos Conda operations in Idaho produced 95,719 mt of P205 during the fourth
quarter, up from the year-ago 89,226 mt, with the company citing production
efficiencies from improved uptime and better recoveries. Conda generated quarterly
adjusted EBITDA of $32.4 million on revenues of $112.4 million, versus the
year-ago $54.8 million and $129.3 million, respectively.
Itafos
reported that its Arraias operation in Brazil successfully started Direct
Application Phosphate Rock (DAPR) production in the fourth quarter by producing
643 mt of P205, compared with zero in the year-ago quarter.
Arraias
produced 34,087 mt of sulfuric acid during the quarter, down from year-ago
35,895 mt, primarily due to reduced sulfuric acid and sulfur inventory
management.
Arraias generated fourth-quarter adjusted EBITDA of $1.1 million, up from the year-ago $0 million, with the increase primarily due to higher sulfuric acid volume and lower costs, as well as the commencement of DAPR sales.
Company-wide,
Itafos remained in the black for full-year 2023, with net income of $3.1
million on revenues of $465.5 million, compared to 2022’s $114.7 million and $593.3
million, respectively. Adjusted EBITDA was $131.8 million, down from $224.8
million.
Full-year
Conda production was 349,030 mt P205, up from 2022’s 343,526 mt. Adjusted EBITDA
was $148.1 million on revenues of $448.1 million, compared with 2022’s $240.2
million and $571.1 million, respectively.
Full-year Arraias sulfuric acid production was down at 89,075 mt from 2022’s 99,030 mt, with Itafos citing a sulfuric acid plant shutdown for required maintenance in April and May. DAPR production was 5,196 mt for the year, versus zero in 2022.
Arraias
generated adjusted EBITDA of $400,000 for the year compared to a $100,000 loss
in 2022. Higher acid volumes were cited, along with lower costs and the
commencement of DAPR sales.